Keywords
Rifabutin
Gastritis
Peptic ulcer
Stomach neoplasms
How to Cite
Abstract
Helicobacter pylori infection is associated with gastroduodenal diseases such as chronic gastritis, peptic ulcer, and gastric adenocarcinoma. Nowadays, there are different therapeutic regimens, however, the indiscriminate use of antibiotics generated resistance in this agent, reason to study alternatives and reevaluate the criteria that determines the selection of a specific regimen. The aim of this review was to describe the general principles of treatment according to reference guidelines and recommendations of independent authors, and to present the use of rifabutin as a therapeutic alternative. The bibliographic search was performed using the terms “Helicobacter pylori” AND “rifabutin” in the databases PubMed, SciELO and the search engine Google Scholar®. Current evidence suggests that the use of rifabutin as rescue therapy is appropriate and safe, and would be an ideal alternative in cases of multidrug resistance or difficult access to antibiotic susceptibility tests. MÉD.UIS.2022;35(1): 31-42.
References
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015. Sep;64(9):1353–67.
Cover TL, Blaser MJ. Helicobacter pylori and other gastric Helicobacter species. En: Bennett JE, Dolin R, Blaser MJ, editores. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Novena edición. Filadelfia: Elsevier;2020. p. 2660-2668.
Contreras M, Salazar V, García-Amado MA, Reyes N, Aparcero M, Silva O, et al. High frequency of Helicobacter pylori in the esophageal mucosa of dyspeptic patients and its possible association with histopathological alterations. Int J Infect Dis. 2012. May;16(5):e364-70.
Salas-Gordillo JF. Gastropatías y gastritis. En: Pérez-Torres E, Abdo-Francis JM, Bernal-Sahagún F, Kershenobich-Stalnikowitz D, editores. Gastroenterología. Nueva York, NY: McGraw-Hill; 2015.
Otero W, Gómez M, Otero L, Trespalacios A. Helicobacter pylori: ¿cómo se trata en el 2018?. Rev gastroenterol Perú. 2018. 38(1):54–63.
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420–429.
Go MF. Review article: Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16 Suppl 1:3–15.
Oluwasola AO. Genetic determinants and clinico-pathological outcomes of helicobacter pylori infection. Ann Ib Postgrad Med [Internet]. 2014;12(1):22-30. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25332697/.
Boehnke KF, Brewster RK, Sánchez BN, et al. An assessment of drinking water contamination with Helicobacter pylori in Lima, Peru. Helicobacter [Internet]. 2018;23(2):e12462. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29316052/.
Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis [Internet]. 2008;198(4):553-560. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18598192/.
Arenillas P. S, Godoy F. A, Einisman F. H, García P. D, Harris D. P. Regulación de la respuesta inmune frente a la infección por Helicobacter pylori. Rev Chil Pediatr [Internet]. 2002;73(2): 108- 115. Disponible en: https://www.revistachilenadepediatria.cl/index.php/rchped/article/view/1848.
Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554-3560.
García C Apolinaria, Barra T Ricardo, Delgado Sch Carolina, Kawaguchi P Fernando, Trabal F Natalia, Montenegro H Sonia et al . Genotipificación de aislados clínicos de Helicobacter pylori en base a genes asociados a virulencia cagA, vacA y babA2: Primer aislamiento de una cepa babA2 positiva en pacientes chilenos. Rev. méd. Chile [Internet]. 2006; 134(8): 981-988. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000800006&lng=es.
Zali H, Rezaei-Tavirani M, Azodi M. Gastric cancer: prevention, risk factors and treatment. Gastroenterol Hepatol Bed Bench [Internet]. 2011;4(4):175-185. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24834180/.
The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993;341(8857):1359–62.
Toh JWT, Wilson RB. Pathways of gastric carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals. Int J Mol Sci. 2020;21(17):6451.
Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol. 2009;104(7):1642–9.
Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67(12):2092–6.
Oliveros R, Pinilla Morales RE, Facundo Navia H, Sánchez Pedraza R. Cáncer gástrico: una enfermedad prevenible. Estrategias para intervención en la historia natural. Rev Colomb Gastroenterol. 2019;34(2):177–89.
Moon JS. Screening Upper Endoscopy for Early Detection of Gastric Cancer. J Korean Med Sci. 2018;33(23):e190.
Fallone CA, Moss SF, Malfertheiner P. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology. 2019;157(1):44–53.
Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord. 2005;5(2):67–72.
Park CS, Lee SM, Park CH, Koh HR, Jun CH, Park SY, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109(10):1595–1602.
Ducournau A, Bénéjat L, Sifré E, Bessède E, Lehours P, Mégraud F. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect. 2016;22(8):715–718.
Arévalo A, Otero WA, Trespalacios AA. Helicobacter pylori: resistencia múltiple en pacientes de Bogotá, Colombia. Biomedica. 2019;39(1):125–134.
Graham DY. Clarithromycin for treatment of Helicobacter pylori infections. Eur J of Gastroenterol Hepatol. 1995; 7(1):55–58.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–239.
Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
Morcillo-Muñoz JA, Regino-Otero WA, Gómez Zuleta MA. Helicobacter pylori: ¿cómo mejorar las terapias de erradicación?. Rev Colomb Gastroenterol. 2018;33(4):437.
Otero R. W, Trespalacios R. AA, Otero P. L, Vallejo O. MT, Torres Amaya M, Pardo R, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Colomb Gastroenterol. 2015;30:17–33.
Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54(3):258–66.
Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, et al. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol. 2016;16(1):80.
Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013;25(10):1134–40.
Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther. 2017;24(6):e751–7.
Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, CastroFernández M, et al. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci. 2015;60(2):458-64.
Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22(4).
Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernández-García T, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109(4):485-95.
Martínez JD, Henao SC, Lizarazo JI. Antibiotic resistance of Helicobacter pylori in Latin America and the Caribbean. Rev Col Gastroenterol. 2014;29(3):218-227.
Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13(9):1616–24.
Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, PoutouPiñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One. 2016;11(7):e0160007.
Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93(12):2330–8.
Veijola L, Myllyluoma E, Korpela R, Rautelin H. Stool antigen tests in the diagnosis of Helicobacter pylori infection before and after eradication therapy. World J Gastroenterol [Internet]. 2005; 11(46):7340-7344. Disponible en: https://dx.doi.org/10.3748%2Fwjg.v11.i46.7340.
Trespalacios AA, Otero Regino W, Mercado Reyes M. Resistencia de Helicobacter pylori a metronidazol, claritromicina y amoxicilina en pacientes colombianos. Rev Col Gastroenterol [Internet]. 2010; 25(1):31-38. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-99572010000100009.
Dore MP, Pes GM. What Is New in Helicobacter pylori Diagnosis. An Overview. J Clin Med [Internet]. 2021; 10(10):2091. Disponible en: https://dx.doi.org/10.3390%2Fjcm10102091.
Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. Highdose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol [Internet]. 2015;13(5):895-905.e5. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25460556/.
Epha.health. [Internet] Zurich. Asesoramiento farmacológico para rifabutina, rifampicina y rilpivirina. Drug information systems. [Internet]. Disponible en: https://epha.health/clinic/advice/es/for-drug-rifabutin-rifampicin-rilpivirin/.
Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs [Internet]. 1994;47(6):983-1009. Disponible en: https://doi.org/10.2165/00003495-199447060-00008.
Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother [Internet]. 1999;43(6):1497-1499. Disponible en: https://journals.asm.org/doi/10.1128/AAC.43.6.1497.
Gisbert JP, Calvet X. Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35(2):209–21.
Ahuja V, Bhatia V, Dattagupta S, Raizada A, Sharma MP. Efficacy and tolerability of rifampicin-based rescue therapy for Helicobacter pylori eradication failure in peptic ulcer disease. Dig Dis Sci. 2005;50(4):630–3.
Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020;172(12):795–802.
US Food and Drug Administration [Internet]. Pfizer/FDA. Mycobutin. FDA Label - SUPPL-26. Reference ID: 4857256 . 2021 sep. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s026lbl.pdf.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Médicas UIS